55 related articles for article (PubMed ID: 20635444)
1. New findings in prostate cancer: highlights from the 23rd annual congress of the European association of urology, march 26-29, 2008, milan, Italy.
Kuehhas FE; Djavan B
Rev Urol; 2008; 10(4):290-3. PubMed ID: 19145272
[No Abstract] [Full Text] [Related]
2. Multiparametric magnetic resonance imaging for pre-treatment local staging of prostate cancer: A Cancer Care Ontario clinical practice guideline.
Salerno J; Finelli A; Morash C; Morgan SC; Power N; Schieda N; Haider MA
Can Urol Assoc J; 2016; 10(9-10):E332-E339. PubMed ID: 27800062
[TBL] [Abstract][Full Text] [Related]
3. The value of prostate MRI with endorectal coil in detecting seminal vesicle involvement in patients with prostate cancer.
Ghafoori M; Alavi M; Shakiba M; Hoseini K
Iran J Radiol; 2015 Jan; 12(1):e14556. PubMed ID: 25793086
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric MRI in prostate cancer management.
Johnson LM; Turkbey B; Figg WD; Choyke PL
Nat Rev Clin Oncol; 2014 Jun; 11(6):346-53. PubMed ID: 24840072
[TBL] [Abstract][Full Text] [Related]
5. The optimal timing of post-prostate biopsy magnetic resonance imaging to guide nerve-sparing surgery.
Ko YH; Song PH; Moon KH; Jung HC; Cheon J; Sung DJ
Asian J Androl; 2014; 16(2):280-4. PubMed ID: 24407179
[TBL] [Abstract][Full Text] [Related]
6. The predictability of T3 disease in staging MRI following prostate biopsy decreases in patients with high initial PSA and Gleason score.
Hwii Ko Y; Jae Sung D; Gu Kang S; Ho Kang S; Gu Lee J; Jong Kim J; Cheon J
Asian J Androl; 2011 May; 13(3):487-93. PubMed ID: 21383671
[TBL] [Abstract][Full Text] [Related]
7. Nomogram to predict insignificant prostate cancer at radical prostatectomy in Korean men: a multi-center study.
Chung JS; Choi HY; Song HR; Byun SS; Seo SI; Song C; Cho JS; Lee SE; Ahn H; Lee ES; Hwang TK; Kim WJ; Chung MK; Jung TY; Yu HS; Choi YD
Yonsei Med J; 2011 Jan; 52(1):74-80. PubMed ID: 21155038
[TBL] [Abstract][Full Text] [Related]
8. Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?
Lee HW; Seo SI; Jeon SS; Lee HM; Choi HY
Yonsei Med J; 2010 Sep; 51(5):700-7. PubMed ID: 20635444
[TBL] [Abstract][Full Text] [Related]
9. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
11. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
12. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
13. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.
Gancarczyk KJ; Wu H; McLeod DG; Kane C; Kusuda L; Lance R; Herring J; Foley J; Baldwin D; Bishoff JT; Soderdahl D; Moul JW
Urology; 2003 Mar; 61(3):589-95. PubMed ID: 12639653
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
